lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== External links == Actinium at The Periodic Table of Videos (University of Nottingham) NLM Hazardous Substances Databank – Actinium, Radioactive Actinium in Kirby, H. W.; Morss, L. R. (2006). Morss; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (3rd ed.). Dordrecht, The Netherlands: Springer. ISBN 978-1-4020-3555-5.
== Mechanism of action == Unlike traditional sulfonylureas, RX871024 not only closes ATP-sensitive potassium (KATP) channels—leading to membrane depolarization, opening of voltage-gated calcium channels, and increased intracellular calcium—but also directly stimulates exocytosis of insulin-containing granules, even under conditions where calcium levels are held constant. This compound inhibits several potassium channels, including KATP, KCa, and delayed rectifier potassium channels, and interacts specifically with the Kir6.2 (KCNJ11) subunit of the KATP channel, distinguishing its mode of action from sulfonylureas, which target the sulfonylurea receptor 1 (ABCC8). Additionally, RX871024 mobilizes calcium from intracellular, thapsigargin-sensitive stores via redox-dependent pathways involving cytochrome P-450. Its insulinotropic effect is further enhanced by activation of protein kinase C and increases in diacylglycerol (DAG) levels, while protein kinase A activity appears to play a permissive role. RX871024 also modulates the phosphorylation of cytosolic proteins such as nonmuscle myosin heavy chain-A, which may be involved in insulin secretion signaling. Collectively, these multifaceted actions make RX871024 a potential lead compound for the development of novel antidiabetic therapies.
Akan languages (Asante Twi, Akuapem Twi, Fante, which have a high degree of mutual intelligibility, and Nzema, which is less intelligible with the above) Dangme Ewe Ga Gonja Kasem Mole–Dagbani languages (Dagaare and Dagbanli) Of these, Asante Twi is the most widely spoken. Because Ghana is surrounded by French-speaking countries, French is also taught in schools and used for commercial and international economic exchanges. Hausa is most widely spoken in the northern part of Ghana especially among the Muslim communities. Since 2005, Ghana has been an associate member of the Organisation internationale de la Francophonie, the global organisation that unites French-speaking countries (84 nations on six continents). In 2005, more than 350,000 Ghanaian children studied French in schools. Since then, its status has been progressively updated to a mandatory language in every junior high school. Ghanaian Pidgin English, also known as Kru English (or in Akan, kroo brofo), is a variety of West African Pidgin English spoken in Accra and in the southern towns. It can be divided into two varieties, referred to as "uneducated" or "non-institutionalized" pidgin and "educated" or "institutionalized" pidgin, the former associated with uneducated or illiterate people and the latter acquired and used in institutions such as universities.
In pharmacology and pharmaceutics, a prototype drug is an individual drug that represents a drug class – group of medications having similar chemical structures, mechanism of action and mode of action. Prototypes are the most important, and typically the first developed drugs within the class, and are used as a reference to which all other drugs are compared.
Ease and cost of synthesis Extended shelf stability Detection of binding events on epitope level, enabling study of i.e. epitope spreading Flexible design for peptide sequence (i.e. posttranslational modifications, sequence diversity, non-natural amino acids ...) and immobilization chemistries Higher batch-to-batch reproducibility
Sources: en.wikipedia.org
== Causes == Prolidase deficiency is the result of mutations on the PEPD gene which is located on the "q", i.e., long, arm of chromosome 19 at region 1, band 3, sub-band 11 (notated as 19q13.11). This gene codes for the prolidase Enzyme, also known as peptidase-D. At least 19 different mutations in the PEPD gene have been identified in individuals affected by the disorder.
== Bone versus cartilage == The primitive skeleton is cartilage, a solid avascular (without blood vessels) tissue in which individual cartilage-matrix secreting cells, or chondrocytes, occur. Chondrocytes do not have intercellular connections and are not coordinated in units. Cartilage is composed of a network of collagen type II held in tension by water-absorbing proteins, hydrophilic proteoglycans. This is the adult skeleton in cartilaginous fishes such as sharks. It develops as the initial skeleton in more advanced classes of animals. In air-breathing vertebrates, cartilage is replaced by cellular bone. A transitional tissue is mineralized cartilage. Cartilage mineralizes by massive expression of phosphate-producing enzymes, which cause high local concentrations of calcium and phosphate that precipitate. This mineralized cartilage is not dense or strong. In the air breathing vertebrates it is used as a scaffold for formation of cellular bone made by osteoblasts, and then it is removed by osteoclasts, which specialize in degrading mineralized tissue. Osteoblasts produce an advanced type of bone matrix consisting of dense, irregular crystals of hydroxyapatite, packed around the collagen ropes. This is a strong composite material that allows the skeleton to be shaped mainly as hollow tubes. Reducing the long bones to tubes reduces weight while maintaining strength.
Ehlers–Danlos syndromes (EDS) are a group of 13 genetic connective tissue disorders. Symptoms often include loose joints; joint pain; stretchy, velvety skin; and abnormal scar formation. These may be noticed at birth or in early childhood. Complications may include aortic dissection, joint dislocations, scoliosis, chronic pain, or early osteoarthritis. The existing classification was last updated in 2017, when a number of rarer forms of EDS were added. EDS occurs due to mutations in one or more of the 19 particular genes which can contribute to the condition. The specific gene affected determines the type of EDS, though the genetic causes of hypermobile Ehlers–Danlos syndrome (hEDS) are still unknown. Some cases result from a new variation occurring during early development. In contrast, others are inherited in an autosomal dominant or recessive manner. Typically, these variations result in defects in the structure or processing of the protein collagen or tenascin. Diagnosis is often based on symptoms, particularly hEDS, but people may initially be misdiagnosed with somatic symptom disorder, depression, or myalgic encephalomyelitis/chronic fatigue syndrome. Genetic testing can be used to confirm all types of EDS except hEDS, for which a genetic marker has yet to be discovered. A cure is not yet known, and treatment is supportive in nature. Physical therapy and bracing may help strengthen muscles and support joints.
I wanted Glenn to know, so I went to his bedside and told him. I thought I saw a gleam in his eye, but the next day when I went to visit him he didn't remember seeing me. As a scientist, he had died when he had that stroke. Seaborg died two months later, on 25 February 1999. In March 1999, the same team replaced the 244Pu target with 242Pu to make other flerovium isotopes. Two atoms of flerovium were produced as a result, each alpha-decaying with a half-life of 5.5 s. They were assigned as 287Fl. This activity has not been seen again either, and it is unclear what nucleus was produced. It is possible that it was an isomer 287mFl or from electron capture by 287Fl, leading to 287Nh and 283Rg.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.